BetaGlue Therapeutics Overview

  • Year Founded
  • 2009

Year Founded

  • Status
  • Private

  • Employees
  • 23

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $8.11M

  • Investors
  • 12

BetaGlue Therapeutics General Information

Description

Developer of a medical platform designed to provide a targeted approach in the treatment of cancer. The company offers a precision radiotherapy platform integrating radiochemistry, medical devices, and localized radiation delivery to deliver targeted treatment for solid tumor cancers, enabling oncology clinicians and healthcare providers to treat solid tumor patients with focused therapy while reducing impact on surrounding tissue.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • Via della Moscova, 3
  • 20121 Milan(Lombardy)
  • Italy
Primary Industry
Drug Discovery
Other Industries
Drug Delivery
Pharmaceuticals
Corporate Office
  • Via della Moscova, 3
  • 20121 Milan(Lombardy)
  • Italy

BetaGlue Therapeutics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

BetaGlue Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
7. Later Stage VC 01-Apr-2025 $8.11M Completed Clinical Trials - Phase 2
6. Later Stage VC 06-Jun-2024 Completed Clinical Trials - Phase 2
5. Grant 08-Nov-2023 Completed Clinical Trials - Phase 2
4. Later Stage VC 19-Jul-2022 Completed Clinical Trials - Phase 2
3. Later Stage VC Completed Clinical Trials - General
2. Later Stage VC 01-Mar-2020 $1.42M $6.1M Completed Clinical Trials - General
1. Later Stage VC (Series A) 19-Oct-2016 $4.68M $4.68M Completed Clinical Trials - General
To view BetaGlue Therapeutics’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

BetaGlue Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a medical platform designed to provide a targeted approach in the treatment of cancer. The company offers a
Drug Discovery
Milan, Italy
23 As of 2026

Woburn, MA
 

Marlborough, MA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

BetaGlue Therapeutics Competitors (2)

One of BetaGlue Therapeutics’s 2 competitors is Sirtex Medical, a Private Equity-Backed company based in Woburn, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Sirtex Medical Private Equity-Backed Woburn, MA
Boston Scientific Corporation Marlborough, MA
You’re viewing 2 of 2 competitors. Get the full list »

BetaGlue Therapeutics Patents

BetaGlue Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025068543-A1 Polymeric radiotherapeutic particles, suspensions and methods for producing same Inactive 29-Sep-2023
WO-2024236123-A1 Compositions, devices and kits for selective internal radiation therapy of hepatocellular carcinoma Inactive 17-May-2023
AU-2021277372-A1 Methods and apparatus for controlled delivery of a sealant Inactive 20-May-2020
CA-3177450-A1 Methods and apparatus for controlled delivery of a sealant Pending 20-May-2020
EP-4153427-A1 Methods and apparatus for controlled delivery of a sealant Inactive 20-May-2020 A61B17/00491
To view BetaGlue Therapeutics’s complete patent history, request access »

BetaGlue Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

BetaGlue Therapeutics Investors (12)

Investor Name Investor Type Holding Investor Since Participating Rounds
Tech and Biomedical Foundation Venture Capital Minority
Angel (individual) Minority
Petrone Group Holding Company Minority
European Innovation Council Accelerator/Incubator Minority
Fin Posillipo Corporation Minority
You’re viewing 5 of 12 investors. Get the full list »

BetaGlue Therapeutics FAQs

  • When was BetaGlue Therapeutics founded?

    BetaGlue Therapeutics was founded in 2009.

  • Where is BetaGlue Therapeutics headquartered?

    BetaGlue Therapeutics is headquartered in Milan, Italy.

  • What is the size of BetaGlue Therapeutics?

    BetaGlue Therapeutics has 23 total employees.

  • What industry is BetaGlue Therapeutics in?

    BetaGlue Therapeutics’s primary industry is Drug Discovery.

  • Is BetaGlue Therapeutics a private or public company?

    BetaGlue Therapeutics is a Private company.

  • What is the current valuation of BetaGlue Therapeutics?

    The current valuation of BetaGlue Therapeutics is .

  • What is BetaGlue Therapeutics’s current revenue?

    The current revenue for BetaGlue Therapeutics is .

  • How much funding has BetaGlue Therapeutics raised over time?

    BetaGlue Therapeutics has raised $49M.

  • Who are BetaGlue Therapeutics’s investors?

    Tech and Biomedical Foundation, , Petrone Group, European Innovation Council, and Fin Posillipo are 5 of 12 investors who have invested in BetaGlue Therapeutics.

  • Who are BetaGlue Therapeutics’s competitors?

    Sirtex Medical and Boston Scientific are competitors of BetaGlue Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process